When genomics companies act as biobanks: governance challenges in an era of genomic assetization

These findings highlight the need for governance approaches that better reflect todays interconnected biobanking ecosystem, which includes public and nonprofit biobanks, government-academic-industry collaborations, and companies operating as <i>de facto</i> biobanks. Strengthening governance may require clearer planning for closure and transition, including limits on the transfer or sale of data and biospecimens during restructuring, possible roles for public stewardship, and a more explicit role for established biobanking institutions in developing shared governance standards across the genomics ecosystem.